AFFIRM: A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Primary Biliary Cholangitis (pbc)
  • Age: Between 18 Year(s) - 75 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Must have a confirmed prior diagnosis of PBC
    2. Evidence of cirrhosis
    3. Females of reproductive potential must use at least 1 barrier contraceptive and a second effective birth control method during the study and for at least

You may not be eligible for this study if the following are true:

    1. Prior use of seladelpar greater than 26 weeks and within 52 weeks of Screening
    2. History of liver transplantation or actively listed for cadaveric or planned living donor transplant. Subjects on the transplant list despite relatively e

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.